Dissolution test for oral suspension: an overview about use and importance
Abstract This work aims to ascertain the comprehensiveness of dissolution tests for oral suspensions registered in Brazil and the USA. After consulting literature since 1994, a paucity of information about dissolution methods for suspensions was detected. It makes it difficult to establish the most...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidade de São Paulo
2022-06-01
|
| Series: | Brazilian Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502022000100603&tlng=en |
| _version_ | 1811342617650135040 |
|---|---|
| author | Thaís dos Santos Paulino Soares Jacqueline de Souza Lorena de Sousa Rosa Flávia Dias Marques-Marinho |
| author_facet | Thaís dos Santos Paulino Soares Jacqueline de Souza Lorena de Sousa Rosa Flávia Dias Marques-Marinho |
| author_sort | Thaís dos Santos Paulino Soares |
| collection | DOAJ |
| description | Abstract This work aims to ascertain the comprehensiveness of dissolution tests for oral suspensions registered in Brazil and the USA. After consulting literature since 1994, a paucity of information about dissolution methods for suspensions was detected. It makes it difficult to establish the most appropriate test parameters. In January, 2019, there were 46 drugs registered in Anvisa (Brazil) as oral suspension, being 47 reference, 173 generic and 114 interchangeable similar (IS) medicines; while in the USA, 90 drugs were registered as oral suspension by FDA, 235 Abreviatted New Drug Application and 111 New Drug Application medicines. Out of 46 and 90, only six and 15 drugs as oral suspension had a pharmacopeial dissolution test, corresponding to 70 (20.9%) and 82 (23.7%) products in Brazil and the USA, respectively. Dissolution studies were found for 17 drugs as oral suspension in the non-compendial literature. Dissolution test conditions were established to few marketable oral suspension drugs, most of which are BCS class II or IV. Thus, investing in dissolution studies could subsidize the registration of these products by regulators, especially for generic and IS drugs, by comparing dissolution profiles, and predicting their in vivo behavior to avoid exposure of healthy individuals to clinical research. |
| first_indexed | 2024-04-13T19:15:08Z |
| format | Article |
| id | doaj.art-d6e92ec7a73f4ea6b3f498466eb34804 |
| institution | Directory Open Access Journal |
| issn | 2175-9790 |
| language | English |
| last_indexed | 2024-04-13T19:15:08Z |
| publishDate | 2022-06-01 |
| publisher | Universidade de São Paulo |
| record_format | Article |
| series | Brazilian Journal of Pharmaceutical Sciences |
| spelling | doaj.art-d6e92ec7a73f4ea6b3f498466eb348042022-12-22T02:33:43ZengUniversidade de São PauloBrazilian Journal of Pharmaceutical Sciences2175-97902022-06-015810.1590/s2175-97902022e19423Dissolution test for oral suspension: an overview about use and importanceThaís dos Santos Paulino SoaresJacqueline de Souzahttps://orcid.org/0000-0003-0869-023XLorena de Sousa RosaFlávia Dias Marques-Marinhohttps://orcid.org/0000-0002-1121-5205Abstract This work aims to ascertain the comprehensiveness of dissolution tests for oral suspensions registered in Brazil and the USA. After consulting literature since 1994, a paucity of information about dissolution methods for suspensions was detected. It makes it difficult to establish the most appropriate test parameters. In January, 2019, there were 46 drugs registered in Anvisa (Brazil) as oral suspension, being 47 reference, 173 generic and 114 interchangeable similar (IS) medicines; while in the USA, 90 drugs were registered as oral suspension by FDA, 235 Abreviatted New Drug Application and 111 New Drug Application medicines. Out of 46 and 90, only six and 15 drugs as oral suspension had a pharmacopeial dissolution test, corresponding to 70 (20.9%) and 82 (23.7%) products in Brazil and the USA, respectively. Dissolution studies were found for 17 drugs as oral suspension in the non-compendial literature. Dissolution test conditions were established to few marketable oral suspension drugs, most of which are BCS class II or IV. Thus, investing in dissolution studies could subsidize the registration of these products by regulators, especially for generic and IS drugs, by comparing dissolution profiles, and predicting their in vivo behavior to avoid exposure of healthy individuals to clinical research.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502022000100603&tlng=enDissolutionSuspensionTherapeutic equivalenceRegulatory |
| spellingShingle | Thaís dos Santos Paulino Soares Jacqueline de Souza Lorena de Sousa Rosa Flávia Dias Marques-Marinho Dissolution test for oral suspension: an overview about use and importance Brazilian Journal of Pharmaceutical Sciences Dissolution Suspension Therapeutic equivalence Regulatory |
| title | Dissolution test for oral suspension: an overview about use and importance |
| title_full | Dissolution test for oral suspension: an overview about use and importance |
| title_fullStr | Dissolution test for oral suspension: an overview about use and importance |
| title_full_unstemmed | Dissolution test for oral suspension: an overview about use and importance |
| title_short | Dissolution test for oral suspension: an overview about use and importance |
| title_sort | dissolution test for oral suspension an overview about use and importance |
| topic | Dissolution Suspension Therapeutic equivalence Regulatory |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502022000100603&tlng=en |
| work_keys_str_mv | AT thaisdossantospaulinosoares dissolutiontestfororalsuspensionanoverviewaboutuseandimportance AT jacquelinedesouza dissolutiontestfororalsuspensionanoverviewaboutuseandimportance AT lorenadesousarosa dissolutiontestfororalsuspensionanoverviewaboutuseandimportance AT flaviadiasmarquesmarinho dissolutiontestfororalsuspensionanoverviewaboutuseandimportance |